Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, has announced its plans to release second quarter 2024 financial results on August 14, 2024, after market close. The company will host a conference call and webcast at 5:00 p.m. ET on the same day to discuss the financial results and provide a corporate update.
Investors and interested parties can access the webcast through the provided link or pre-register for the conference call. A replay of the call will be available on the company's website in the 'For Investors' section, and the webcast will remain accessible for 90 days following the live call.
Plus Therapeutics (Nasdaq: PSTV), un'azienda farmaceutica in fase clinica concentrata nello sviluppo di radioterapie mirate per i tumori del sistema nervoso centrale, ha annunciato i suoi piani per rilasciare i risultati finanziari del secondo trimestre del 2024 il 14 agosto 2024, dopo la chiusura del mercato. L'azienda organizzerà una conferenza telefonica e una diretta streaming alle 17:00 ET dello stesso giorno per discutere i risultati finanziari e fornire un aggiornamento aziendale.
Gli investitori e le parti interessate possono accedere alla diretta streaming tramite il link fornito o pre-registrarsi per la conferenza telefonica. Una registrazione della chiamata sarà disponibile sul sito web dell'azienda nella sezione 'Per gli Investitori', e la diretta rimarrà accessibile per 90 giorni dopo la chiamata in diretta.
Plus Therapeutics (Nasdaq: PSTV), una compañía farmacéutica en etapa clínica enfocada en desarrollar radioterapias dirigidas para cánceres del sistema nervioso central, ha anunciado sus planes para publicar los resultados financieros del segundo trimestre de 2024 el 14 de agosto de 2024, después del cierre del mercado. La compañía llevará a cabo una conferencia telefónica y una transmisión en vivo a las 5:00 p.m. ET del mismo día para discutir los resultados financieros y proporcionar una actualización corporativa.
Los inversionistas y partes interesadas pueden acceder a la transmisión en vivo a través del enlace proporcionado o pre-registrarse para la conferencia telefónica. Se ofrecerá una reproducción de la llamada en el sitio web de la empresa en la sección 'Para Inversionistas', y la transmisión en vivo permanecerá accesible durante 90 días después de la llamada en vivo.
플러스 테라퓨틱스(나스닥: PSTV)는 중앙 신경계 암을 위한 표적 방사선 치료제를 개발하는 임상 단계의 제약회사로, 2024년 2분기 재무 결과를 2024년 8월 14일에 시장 마감 후 발표할 계획을 발표했습니다. 회사는 같은 날 오후 5시 ET에 재무 결과를 논의하고 기업 업데이트를 제공하기 위해 전화 회의 및 웹캐스트를 개최할 예정입니다.
투자자와 관심 있는 당사자는 제공된 링크를 통해 웹캐스트에 접근하거나 전화 회의에 사전 등록할 수 있습니다. 회의 재생은 회사 웹사이트의 '투자자' 섹션에서 이용 가능하며, 웹캐스트는 라이브 호출 후 90일 동안 계속 접근할 수 있습니다.
Plus Therapeutics (Nasdaq: PSTV), une entreprise pharmaceutique en phase clinique axée sur le développement de radiothérapies ciblées pour les cancers du système nerveux central, a annoncé ses projets de publication de résultats financiers du deuxième trimestre 2024 le 14 août 2024, après la clôture du marché. L'entreprise accueillera une conférence téléphonique et une diffusion en direct à 17h00 ET le même jour pour discuter des résultats financiers et fournir une mise à jour sur l'entreprise.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via le lien fourni ou préenregistrer pour la conférence téléphonique. Un enregistrement de l'appel sera disponible sur le site Web de l'entreprise dans la section 'Pour les investisseurs', et la diffusion en direct restera accessible pendant 90 jours après l'appel en direct.
Plus Therapeutics (Nasdaq: PSTV), ein pharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung gezielter Radiotherapien für Krebs des zentralen Nervensystems konzentriert, hat seine Pläne bekannt gegeben, die Finanzergebnisse des zweiten Quartals 2024 am 14. August 2024 nach Börsenschluss zu veröffentlichen. Das Unternehmen wird am selben Tag um 17:00 Uhr ET eine Telefonkonferenz und ein Webcast abhalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Investoren und Interessierte können über den bereitgestellten Link auf den Webcast zugreifen oder sich für die Telefonkonferenz vorregistrieren. Eine Wiederholung des Anrufs wird im 'Für Anleger'-Bereich der Unternehmenswebsite verfügbar sein, und der Webcast wird 90 Tage lang nach dem Live-Anruf zugänglich bleiben.
- None.
- None.
AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report second quarter 2024 financial results on Wednesday, August 14, 2024, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
| Webcast and Conference Call | |
| Date/Time: | Wednesday, August 14, 2024 @ 5:00 PM ET |
| Webcast: | https://edge.media-server.com/mmc/p/mtnrwhh5 |
| Dial-in Link: | https://register.vevent.com/register/BI1c575c6aa37840b9872f3ad10091195c |
Participants are encouraged to pre-register any time before the call through the dial-in link. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company’s website under the ‘For Investors’ section. The webcast will be available on the Company’s website for 90 days following the live call.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a robust supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186Re including the ability of 186Re to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186Re; the continued evaluation of 186Re including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Charles Y. Huang, MBA
Director of Capital Markets and Investor Relations
Office: (202)-209-5751 | Direct (301)-728-7222
chuang@plustherapeutics.com
FAQ
When will Plus Therapeutics (PSTV) release its Q2 2024 financial results?
What time is Plus Therapeutics' (PSTV) Q2 2024 earnings call scheduled for?
How can investors access Plus Therapeutics' (PSTV) Q2 2024 earnings call?
Will a replay of Plus Therapeutics' (PSTV) Q2 2024 earnings call be available?
